CAR-T (Chimeric Antigen Receptor T-cell) therapy is widely regarded as one of the most groundbreaking innovations in cancer treatment in recent years. As CAR-T technology continues to advance, more patients are exploring treatment options in different countries.

So, what are the key differences between CAR-T therapy in China, the United States, and Japan? And how should patients choose the most suitable treatment destination?

In this article, HongKong DengYueMed analyzes CAR-T therapy from four perspectives: treatment costs, technological development, clinical trials, and accessibility for international patients.

What Is CAR-T Therapy?

CAR-T (Chimeric Antigen Receptor T-cell Therapy) is a personalized cell therapy that uses a patient's own immune cells to fight cancer.

In simple terms, doctors collect T cells from the patient, genetically modify them in a laboratory so they can recognize specific targets on cancer cells, and then infuse these enhanced T cells back into the patient's body to attack and destroy tumor cells.

Currently, CAR-T therapy is primarily used for:

● B-cell Acute Lymphoblastic Leukemia (ALL)

● Diffuse Large B-Cell Lymphoma (DLBCL)

● Follicular Lymphoma (FL)

● Mantle Cell Lymphoma (MCL)

● Multiple Myeloma (MM)

In recent years, CAR-T research has also expanded into solid tumors, including liver cancer, gastric cancer, and lung cancer.

CAR-T Treatment Cost Comparison: United States, Japan, and China

Treatment cost is one of the most important considerations for patients seeking CAR-T therapy.

United States

The United States has the most mature commercial CAR-T market in the world.

Multiple CAR-T products have been approved for indications such as lymphoma, leukemia, and multiple myeloma. However, the U.S. also has the highest treatment costs globally.

The total cost typically includes:

● CAR-T product costs

● Hospitalization fees

● ICU monitoring and care

● Lymphodepletion chemotherapy

● Management of treatment-related adverse events

Overall treatment costs often exceed:

USD 500,000 to USD 1,000,000+

For international patients without comprehensive insurance coverage, the financial burden can be substantial.

Japan

Japan was one of the first countries in Asia to approve CAR-T therapies.

Its healthcare system is highly developed, and treatment quality is excellent. However, CAR-T therapy remains relatively expensive.

The total treatment cost is typically:

25 million to 50 million Japanese Yen

Equivalent to approximately:

USD 170,000 to USD 350,000

International patients should carefully plan for both medical expenses and living costs during treatment.

China

China's CAR-T industry has developed rapidly in recent years.

With the approval of domestic CAR-T products and increasing clinical experience among hospitals, treatment costs in China are significantly lower than those in the United States and Europe.

Depending on the treatment plan, hospital, and CAR-T product used, total costs generally range from:

RMB 800,000 to RMB 2,000,000

Equivalent to approximately:

USD 110,000 to USD 280,000

Compared with the United States, China offers a more cost-competitive option while maintaining high-quality medical care.

For self-paying international patients, China is becoming an increasingly attractive destination for CAR-T therapy.

Approved CAR-T Indications: United States, Japan, and China

The pace of CAR-T development is closely linked to each country's regulatory framework.

United States

The United States has one of the largest numbers of approved CAR-T products worldwide.

Approved indications currently include:

● Acute Lymphoblastic Leukemia (ALL)

● Large B-Cell Lymphoma

● Primary Mediastinal Large B-Cell Lymphoma

● Follicular Lymphoma

● Mantle Cell Lymphoma

● Multiple Myeloma

As a result, the U.S. offers one of the broadest ranges of approved CAR-T applications.

Japan

Japan's approved indications are largely aligned with those in the United States.

They mainly focus on:

● B-cell Leukemia

● Lymphomas

● Multiple Myeloma

Due to a smaller patient population, new product approvals generally progress at a slower pace than in the U.S.

China

China has approved multiple CAR-T therapies for clinical use.

If you would like to learn more about approved CAR-T products in China, please refer to our related article: Approved Cell and Gene Therapy Drugs in China and Key Differences Between Cell Therapy and Gene Therapy

Approved indications currently include:

● Relapsed or Refractory Large B-Cell Lymphoma

● Multiple Myeloma

● Adult Acute Lymphoblastic Leukemia

At the same time, China has become highly active in solid tumor CAR-T research.

Current research areas include:

● Liver Cancer

● Gastric Cancer

● Pancreatic Cancer

● Lung Cancer

● Ovarian Cancer

● Glioblastoma

Although most solid tumor CAR-T therapies remain in clinical development, China has emerged as one of the world's most active centers for this field of research.

Clinical Trial Activity Comparison

The number of clinical trials often reflects a country's level of innovation in advanced therapies.

United States

The United States is home to many of the world's leading research institutions and biotechnology companies.

For decades, it has remained a global hub for CAR-T innovation.

Representative institutions include:

● MD Anderson Cancer Center

● Memorial Sloan Kettering Cancer Center

● Mayo Clinic

● University of Pennsylvania

Japan

Japan also possesses strong research capabilities.

However, due to its smaller population and market size, the number of CAR-T clinical trials is relatively lower than in China and the United States.

Its key strengths include:

● High-quality research

● Strict regulatory oversight

● Comprehensive long-term follow-up systems

China

China has seen rapid growth in CAR-T clinical research over the past several years.

In some years, the number of registered CAR-T clinical trials in China has even exceeded that of the United States.

Research areas cover a wide range of targets, including:

● CD19

● BCMA

● GPC3

● Claudin18.2

● Mesothelin

● HER2

Particularly in the field of solid tumors, China has demonstrated strong innovation capabilities.

For patients with limited standard treatment options, participation in clinical trials may provide access to promising new therapies.

Accessibility for International Patients

For international patients, advanced technology is only one factor when choosing a treatment destination. Access to treatment is equally important.

The United States offers world-renowned cancer centers and extensive CAR-T experience. However, high treatment costs, complex insurance requirements, and waiting times at some institutions can present challenges.

International patients considering treatment in the U.S. should pay attention to:

● High medical costs

● Insurance coverage requirements

● Hospital scheduling and waiting times

● Visa and travel arrangements

Japan provides a highly organized healthcare system and excellent quality of care. However, international patient programs remain relatively limited, and language or administrative barriers may make access more challenging.

In recent years, many leading Chinese hospitals have established international medical service departments. Some institutions now offer medical record reviews, remote consultations, medical interpretation, international wards, and post-treatment follow-up services.